Plain-English translation of NCT06676280 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 4 β The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The ASA-3C trial is testing whether and therapy (strong cholesterol-lowering medications) can help prevent heart attacks and strokes in people who have significant calcium buildup in their coronary arteries. Researchers want to understand which combination of these medications works best for people like you who have risk factors for heart disease but haven't yet had a heart attack or stroke.
People with calcium buildup in their heart arteries are at higher risk for heart disease, but doctors aren't sure whether alone, strong cholesterol medications alone, or both together provide the best protection. This trial will help answer that question and guide future treatment decisions.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will be randomly assigned to take one of four combinations of medications: plus strong cholesterol medication, plus standard cholesterol medication, strong cholesterol medication alone, or standard cholesterol medication alone. You'll take your assigned medications daily and return for regular follow-up visits where doctors will check your health, run blood tests, and monitor you for any side effects. The study will track your health over time to see which medication approach best prevents heart attacks and strokes.
AI-generated summary from trial data Β· Jul 4, 2026 Β· Not medical advice
South Korea